)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Cipla
Cipla (CIPLA) investor relations material
Cipla Q2 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 25/26 earnings summary30 Oct, 2025
Executive summary
Achieved record quarterly revenue of INR 7,589 crore in Q2FY26, up 8% year-over-year, with robust profitability and strong performance across India, U.S., Africa, and EMEU markets.
EBITDA reached INR 1,895 crore (25% of revenue), and PAT was INR 1,351 crore (17.8% of revenue), both showing year-over-year growth.
Maintained leadership in chronic therapies, expanded consumer health, and launched new products in North America and Africa, including entry into obesity care with tirzepatide (Yurpeak) via Eli Lilly partnership.
U.S. business saw $233 million in revenue, with leadership in albuterol MDI and the launch of the first biosimilar (filgrastim).
Unaudited consolidated and standalone financial results for the quarter and half year ended 30th September 2025 were approved and released, with statutory auditors providing an unmodified review conclusion.
Financial highlights
Quarterly revenue grew 8% year-over-year to INR 7,589 crore, the highest ever, with half-year consolidated revenue at INR 14,546.91 crore.
EBITDA margin at 25%; gross margin at 67%; PAT margin at 17.8% of revenue.
Profit after tax was INR 1,351 crore for the quarter and INR 2,644.98 crore for the half year.
R&D investment for the quarter was INR 539 crore (7.1% of revenue), trending higher due to accelerated filings and new programs.
Net cash balance at INR 9,901 crore after debt and dividend payout; cash and cash equivalents increased to INR 10,368 crore year-over-year.
Outlook and guidance
Full-year EBITDA margin guidance revised to 22.75%-24% (from 23.5%-24.5%), excluding Yurpeak business, due to higher R&D spend and lower Revlimid contribution.
India business aims to regain growth momentum and outperform the market in branded and trade generics.
U.S. business expects continued growth in base business, with minimal Revlimid contribution in coming quarters and a sales target of $1 billion next year, contingent on timely approvals.
Pipeline includes four major respiratory launches (including generic Advair) and three peptide assets by 2026.
Management expects a favorable outcome in ongoing litigation with the NPPA and has not made provisions for the related demand notices.
Cipla's stance on NPPA litigation provision?
What business was acquired for
130 Crores?
Explain New Ventures segment revenue decline.
Yurpeak: What is the market shaping strategy?
U.S. growth drivers post-Revlimid decline?
EBITDA margin: Drivers for revised FY26 guidance?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Cipla earnings date
Q3 25/2623 Jan, 2026
Cipla
Next Cipla earnings date
Q3 25/2623 Jan, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Cipla Limited is an India-based pharmaceutical company engaged in the development, manufacturing, and distribution of generic and branded medicines. The company’s product range spans respiratory, cardiovascular, anti-infective, and other therapeutic areas. Cipla Limited is headquartered in Mumbai, India, and its shares are listed on the NSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage